THERAPEUTIC ANTIBODY DISCOVERY
When tasked with difficult therapeutic targets (cell surface, multispanning transmembrane proteins, glycoproteins, etc.) there are a few things that make Abveris uniquely equipped to deliver with the best chance of success. This includes our comprehensive services, immunization expertise, and access to leading discovery platforms.
Work at Abveris is industry-leading as well as milestone and royalty-free!
包括的サービス
早期段階
When working on unique targets, it may be difficult to find reliable reagents, namely proteins and/or cell lines. Our protein and cell line generation capabilities help to ensure that the appropriate amounts of immunization and screening materials are available. Once the project is complete, all remaining material are sent to our partners so that the materials can continue to be used as needed.
中期段階：探索・スクリーニング
Beacon での B 細胞スクリーニングと最適化されたハイブリドーマ開発プロセスにより、大規模かつ多様な mAb 群を発見することができます。
当社の一連のハイスループットスクリーニングおよび特性評価プラットフォームにより、理想的なバインダーを同定できるだけでなく、探索プロセスの早期に高親和性かつ機能的に関連する抗体をスクリーニングすることもできます。ハイスループットフローサイトメトリーにより、機能面の活性だけではなく、細胞上での結合も解析することが可能です。
後期段階
Next-generation sequencing efforts are accompanied by custom data reports that highlight developability concerns and deliver more value. 組換え抗体作製では、パートナーは信頼性の高い哺乳類細胞株でご希望の抗体を大量に作製することが可能です。
免疫に関する専門知識
Abveris は、免疫に関する専門知識と幅広い能力を有していることに自信を持っています。免疫の方法は以下の通りです。
- ペプチド・タンパク質を用いた免疫
- 細胞を用いた免疫
- 免疫サブトラクション法による細胞を用いた免疫
- DNA を用いた免疫
- VLP を用いた免疫
- 免疫寛容の破壊
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as 3 weeks, enabling rapid antibody discovery. 当社は独自のアジュバントや免疫プロトコルを有しており、当社独自のマウス系統の過剰免疫および自己免疫の特徴を活用して、交差反応性のある多様な抗体セットの開発可能性をより高めています。さまざまなヒト化プラットフォームを用いた研究を通じて、治療法開発の取り組みでよく用いられるマウスモデルに適用できるよう免疫法を最適化しました。
業界をリードする探索プラットフォーム
Abveris leverages a number of high throughput platforms for antibody screening and characterization. そうしたプラットフォームには、ハイスループット ELISA 用 TECAN システム、ハイスループット on cell スクリーニング用 iQue フローサイトメトリー、抗体キネティクス解析用 Carterra SPR および Octetが含まれます。
Our Toolbox
- Antigen and screening materials development
- Delivery of fully human mAbs using humanized mice from Alloy and Harbour
- Proprietary, hyper-immune DiversimAb mice to generate a more diverse mAb response than wild-type mice
- Multiple immunization techniques including: DNA immunization, cell immunization, rapid protocols, adjuvants to break tolerance and assist in cross-reactivity and more
- Highly efficient B cell screening (Beacon) and hybridoma approaches
- High-throughput, industry-leading screening tools to identify ideal mAbs including the iQue flow cytometer along with the Octet and Carterra systems for affinity, activity and epitope binning analysis.
- In-house sequencing capabilities
- Scale-up and purification of mAb from hybridoma or recombinantly
ANTI-IDIOTYPE ANTIBODY DISCOVERY
At Abveris, we deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
- High-speed offerings
- 94% success-rate delivering on our partner's goals
- Stringent screening packages
- Diverse assay candidates delivered
これらの mAb が臨床アッセイ開発において重要なツールであり、高品質な試薬を迅速に提供することが最終的には患者さんの命に影響することを理解しています。当社チームは、お客様の臨床試験をサポートするために業界随一のスピードで最高品質の抗体を提供することに専心しています。
CELL SURFACE TARGETING MABS
Our Secrets to Success
SELECT PROPER IMMUNOGENS
It is often challenging to present cell surface targets with proper conformation and post-translational modifications. Abveris applies innovative cell-based and DNA-based immunization protocols for cell surface immunogens to maintain the integrity of their complex structures. For certain targets and applications, recombinant proteins and peptide strategies may also provide value.
ABVERIS DIVERSIMAB™ TECHNOLOGY
The proprietary Abveris DiversimAb™ mouse provides the best in vivo option for generating monoclonal antibodies against membrane targets. DiversimAb™ technology can be applied to generate diverse panels of antibodies against tough targets, even when there are very few surface epitopes available. Abveris welcomes humanized mouse strains for fully human therapeutic antibody discovery, or knockout strains at the request of our partners.
HIGH-THROUGHPUT CELL BINDING ANALYSIS
The critical metric for success in antibody discovery for membrane targets is “on-cell binding,” thus necessitating frequent use of flow cytometry screening. The use of high-throughput flow cytometry technology unlocks the ability to screen massive panels of hybridomas with high resolution in hours instead of days.
REPERTOIRE MINING
Nature often has the superior power to utilize the diversity of immune repertoire to provide innovative insights into antibody engineering that rational design approaches may easily accomplish.
In conjunction with Abveris' proprietary hyperimmune mouse family (DievrsimAbTM Platform) and advanced screening technologies, the Hit Expansion Workflow offers opportunities to harness the power of natural repertoire diversity to expand the sequence space for rare, functionally-relevant hits, while increasing the success of antibody discovery against challenging therapeutic targets.
